Find Out More

The GLP-1 Reckoning: Six Tensions Reshaping Food—and Why Behavior Holds the Answer

GLP-1 medications aren’t just suppressing appetites. They’re dismantling the business models the food industry was built on.

With 12% of U.S. adults now using GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound—and adoption projected to reach 30–50 million Americans within the decade—the food industry faces its most significant demand-side disruption since the low-fat movement of the 1990s. JPMorgan estimates $30–55 billion in annual food and beverage sales could evaporate by 2030. In Europe, the wave is building more slowly (~2% adoption), but analysts warn the window to prepare is closing fast.

This isn’t a diet trend. It’s a structural shift in how, when, why, and how much people eat. And the greatest challenge for food companies isn’t reformulating products—it’s understanding the behavioral reality underneath.

What GLP-1 Actually Changes

The mechanism is straightforward: GLP-1 drugs mimic a natural hormone that slows gastric emptying, suppresses appetite, and increases satiety. The behavioral consequences are anything but simple.

Users don’t just eat less—they experience food differently. Appetite drops. “Food noise” quiets. Familiar pleasures lose their pull. Eating occasions shrink from 4–5 to 2–3 per day. And critically, users don’t necessarily switch to healthier foods—they simply consume less of everything, with the sharpest declines in impulse-driven, calorie-dense categories.

For an industry optimized around volume, frequency, and impulse, this is a demand shock with few precedents.

Six Tensions Food Companies Can’t Ignore

A comprehensive review of recent industry media, trade analysis, and company strategy reveals six core tensions that define the GLP-1 challenge. Each one exposes a strategic fault line—and each one demands behavioral, not just nutritional, thinking to resolve.

1. Portion Size vs. Value Perception

58.5% of diners want smaller portions, but selling less food threatens margins. GLP-1 users average 2–3 eating occasions daily instead of 4–5. Some 24% are already ordering from kids’ menus—training high-intent customers to buy the lowest-margin items on the menu.

The winners are brands reframing value around satiety per occasion rather than volume per dollar. Chipotle’s high-protein chicken cup (~32g protein, latte price point) is described as “a value play without any discount.” The losers are operators with rigid portion architectures who can’t adapt.

2. Protein Fortification vs. Taste and Cost

GLP-1 users face a muscle-loss crisis: up to 39% of weight lost on semaglutide is lean body mass, requiring 60–130g of daily protein. Every bite must count when users eat 50% less. But adding protein changes texture, impacts taste, and significantly increases ingredient costs—creating pricing tension in an already affordability-constrained retail environment.

Reformulation is necessary but not sufficient. The real question is: which eating moments actually demand protein, and in what sensory form?

3. “GLP-1 Friendly” Labeling vs. Mainstream Appeal

This is the industry’s most contentious marketing tension. While “GLP-1 Friendly” labels are proliferating, 37.4% of consumers actively reject anything labeled with the drug name. The reason? Social stigma. Dining out is a social act, and no one wants to disclose a medication choice to a server or a table of friends.

Meanwhile, 56.9% of consumers who say they’ll never use GLP-1 drugs still want smaller, protein-forward options. The market for this menu shape is roughly 5× the size of the medicated population. Nestlé’s Vital Pursuit line tells the story: 77% of its sales come from non-GLP-1 households.

The implication is clear: labeling for a medication boxes you into a niche. Designing for a behavior opens a mainstream market.

4. Indulgence vs. Health Positioning

GLP-1 users report reduced cravings for ultra-processed, high-fat, sugary foods—but they still want emotionally satisfying eating experiences in their limited occasions. This paradox—purpose-led eating that still craves pleasure—defines the new innovation frontier.

Products that win sit at the intersection of indulgence and function. Those that lean too far toward “health food” get relegated to specialty aisles. Those that ignore nutritional density lose the eating occasion entirely.

5. Reformulation Investment vs. Uncertain ROI

Is this a 10-year structural transformation—or a 3–5 year cycle that will moderate? Companies must invest billions while the answer remains unclear.

Goldman Sachs projects $60–80 billion in annual food spending will be influenced by GLP-1 by 2028. EY-Parthenon estimates up to $12 billion in snack food market growth could be lost over a decade. The first movers are capturing territory; the hesitators are gambling that the trend will pass.

6. Mainstream vs. Medical Positioning

Is GLP-1 a medical trend requiring specialized products—or a mainstream dietary shift affecting all consumers? The data suggests the latter. 35% of all restaurant consumers, medicated or not, are ordering smaller portions for health reasons. Protein and fiber trends are driving 2026 innovation independent of GLP-1, fueled by broader healthspan and gut-health goals.

The smartest companies are treating GLP-1 as an accelerant of a broader behavioral shift, not as a standalone segment.

💡 Innovation Playbook: Seven Behavioral Moves for the GLP-1 Era

The companies winning in this landscape are re-thinking when, why, and how consumers engage with food. Here’s how to start:

1. Map the new occasion architecture. Identify the “protected moments” and innovate for those first.

2. Design for behavior, not for a diagnosis. Frame products around functional benefits, not around a prescription.

3. Compete on satiety economics, not volume. Think latte pricing for nutrient-dense snacks.

4. Solve the protein-taste tension with sensory intelligence. Identify which textures, flavors, and formats signal “worth it” in a purpose-led eating moment.

5. Build flexible portion architecture.  Offer scalable formats across your highest-velocity products.

6. Test fast with digital-first iteration. Speed of learning is a competitive advantage.

7. Understand the emotional middle ground. GLP-1 users live in a tension between relief (quieter cravings, weight loss) and loss (favorite foods no longer satisfy). Worthy products will honor both.

Webinar: Co-creation for a GLP-1 Snacking Moment Cast Study

IFF is leading clients into creative innovations for consumers adopting eating habits of GLP-1 users.  In this webinar, we walk through a co-creation process.

View Here
Why Reformulation Alone Won’t Win

Here’s what most industry coverage misses: the six tensions above are not primarily technical problems. They are behavioral ones.

Reformulating a snack with more protein doesn’t solve the question of when a consumer reaches for it, why it fits their new emotional relationship with food, or how it earns a place in a dramatically smaller set of eating occasions. Slapping a “GLP-1 Friendly” label on a package doesn’t address the social stigma of disclosing medication use—or the much larger non-medicated audience seeking the same functional benefits.

Traditional approaches—reformulate the product, resize the package, test the concept—work from the outside in. They start with the product and hope it finds a behavioral fit.

Behavioral intelligence works from the inside out. It starts with the moment: the precise intersection of context, internal needs, and external motivators that drives a consumer decision. When any one of these shifts—as GLP-1 so dramatically demonstrates—behavior shifts, even if the category stays the same.

 

Applying a BehaviorLens® to the GLP-1 Challenge

InsightsNow’s BehaviorLens® frameworks bring structure to this complexity—providing behavioral methods, measures, and metrics that reveal how consumers actually make choices. 
A BehaviorLens® integrates:
• Behavioral metrics (predictors like reach, habit strength, opportunity)
• Behavioral measures (real-world actions like choice, usage, repeat behavior)

Together, they move teams beyond attitudes and opinions to evidence-based understanding of behavior.  In a world where GLP-1 is breaking habits at scale, this level of clarity is no longer optional.

Why GLP-1 Demands Human-Centered Design

GLP-1 isn’t just changing what people eat—it’s changing how they relate to food entirely.  This is why human-centered design must lead.

Human-centered design begins with:
• The moment
• The need being resolved
• The emotional and functional outcome required

Then it works outward to design products, formats, and experiences that achieve that behavioral impact.  This flips the traditional question:

From: What product should we make?
To: Which behaviors are worth designing for—and how do we win them?

How IFF Turned Behavioral Disruption into Innovation Opportunity

IFF faced this exact challenge.  They had deep research on GLP-1—multiple studies, reports, and insights—but struggled to translate it into clear innovation direction.

Working with InsightsNow, IFF applied a behavior-first approach:

• Built a behavioral knowledge base across research, social data, and expertise
• Identified distinct GLP-1 snacking moments using behavioral metrics 
• Evaluated each moment based on opportunity, habit disruption, and fit
• Selected high-value moments aligned with business strengths

This reframed the problem entirely:  Not “what products to create” But which moments to win

The result was a set of innovation-ready concepts and a complete playbook connecting behavior to product, formulation, and marketing decisions.  Most importantly, IFF shifted from reacting to trends to leading with behaviorally grounded solutions.

From Weeks to Hours: The Speed of Behavioral Intelligence

Traditional front-end innovation takes months.
With behavioral intelligence:

• Moments discovery happens in hours
• Concept development happens in days
• Innovation cycles compress dramatically 

This isn’t just faster—it’s fundamentally different.  Because instead of starting from scratch each time, teams build on a living behavioral intelligence that compounds with every project.

What Behavioral Intelligence Actually Is

Behavioral intelligence goes beyond insight.

• Insights tell you what happened
• Behavioral insights tell you why
• Behavioral intelligence tells you what to do next

It integrates functional, emotional, social, and psychological drivers into a unified understanding of behavior—and translates that into action.
For GLP-1, that means understanding:

• The new definition of satisfaction
• The emotional trade-offs consumers navigate
• The social signals shaping choice
• The identity shifts behind decision-making

And using that to guide innovation.

How Claira Makes It Possible

Claira™, from InsightsNow, is built to operationalize this approach—delivering human-centered design, powered by behavioral intelligence.

Claira transforms fragmented data into:

• A structured behavioral knowledge base
• Identified moments of opportunity
• Concept-ready innovation playbooks

And supports teams across the entire innovation process—from discovery through execution.
For IFF, this meant:

• Synthesizing massive data sets into clear direction
• Moving from insight to concept in days
• Aligning cross-functional teams around a shared behavioral language

The result is not just faster innovation—but better innovation, grounded in how people actually behave.

The Window Is Closing

With oral GLP-1 pills entering the market in 2026, adoption is poised to accelerate further. Canadian adoption has already doubled in a year. European companies have time—but not much. And in North America, the first movers are already capturing positioning territory that will be difficult to reclaim.

The food industry’s winners in the post-GLP-1 landscape won’t be the ones who reformulate fastest. They’ll be the ones who understand behavior most deeply—who can see the moments re-forming around new consumer realities and design products, messaging, and experiences that fit.

The question is no longer if the industry must adapt. It’s how fast—and whether you’re innovating from data or from behavioral intelligence.

About InsightsNow
InsightsNow helps CPG innovation teams move from data overload to behavioral clarity through human-centered design, powered by behavioral intelligence. Our proprietary BehaviorLens® frameworks reveal the moments, tensions, and drivers that shape consumer choice. Claira™ compresses front-end innovation cycles—helping teams move from discovery to actionable concepts in days, not months.